Circadian variation of urinary eosinophil protein X in asthmatic and healthy children

Clinical and Experimental Allergy

Volumn 29, Issue 11, 1999, Pages 1497-1501

  Storm Van's Gravesande, K ^a   Mattes, J ^a   Gruntjens T ^a   Kopp, M ^a   Seydewitz, H H ^a   Moseler, M ^a   Kuehr, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Airway inflammation; Asthma; Children; Circadian variation; Eosinophil protein X; Therapy monitoring; Urine

Indexed keywords

BUDESONIDE; CREATININE; PROTEIN; STEROID;

ADOLESCENT; ARTICLE; ASTHMA; CHILD; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; MALE; MONITORING; PRIORITY JOURNAL; RADIOIMMUNOASSAY; URINE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ASTHMA; BLOOD PROTEINS; BUDESONIDE; CHILD; CHILD, PRESCHOOL; CIRCADIAN RHYTHM; EOSINOPHIL-DERIVED NEUROTOXIN; EOSINOPHILS; FEMALE; HUMANS; MALE; RIBONUCLEASES;

EID: 0032708291     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1999.00731.x     Document Type: Article

References (24)

1. 1 Warner JO. Impact of the quality of management of asthmatic children by monitoring of inflammation. Allergy 1993; 49:158-61.
2. 2 Bousquet J, Chanez P, Lacoste JY et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323:1033-9.
3. 3 Durham SR, Loegering DA, Dunette S, Gleich GJ, Kay AB. Blood eosinophils and eosinophil-derived proteins in allergic asthma. J Allergy Clin Immunol 1989; 84:931-6.
4. 4 Reimert CM, Poulsen LK, Bindslev-Jensen C, Kharazmi A, Bendtzen K. Measurement of eosinophil cationic protein (ECP) and eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN). Time and temperature dependent spontaneous release in vitro demands standardized sample processing. J Immunol Methods 1993; 166:183-90.
5. 5 Seminario MC, Gleich GJ. The role of eosinophils in the pathogenesis of asthma. Current Opinion Immunology 1994; 6:860-4.
6. 6 Robinson DS, Assoufi B, Durham SR, Kay AB. Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) concentrations in serum and bronchial lavage fluid in 1 asthma. Effect of prednisolone treatment. Clin Exp Allergy 1995; 25:1118-27.
7. 7 O'Byrne PM, Inman MD. Induced Sputum to assess airway inflammation in asthma. Eur Respir J 1996; 9:2435-6.
8. 8 Cottin V, Deviller P, Tardy F, Cordier JF. Urinary eosinophil-derived neurotoxin/protein X. A simple method for assessing eosinophil degranulation in vivo. J Allergy Clin Immunol 1998; 101:116-23.
9. 9 Reimert CM, Minuva U, Kharazmi A, Bendtzen K. Eosinophil protein X/eosinophil derived protein (EPX/EDN). Detection by enzyme-linked immunosorbent assay and purification from normal human urine. J Immunol Methods 1991; 141:97-104.
10. 10 Grigg J, Venge P. Inflammatory markers of outcome. Eur Respir J 1996; 9:16-21.
11. 11 Hoekstra MO, Hovenga H, Gerritsen J, Kauffman HF. Eosinophils and eosinophil-derived proteins in children with moderate asthma. Eur Respir J 1996; 9:2231-5.
12. 12 Adelroth E, Rosenhall L, Johansson SA, Linden M, Venge P. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effect of antiasthmatic treatment with budesonide or terbutaline. Am Rev Respir Dis 1990; 142:91-9.
13. 13 Kristjánsson S, Strannegard IL, Strannegard Ö, Peterson C, Enander I, Wennergren GJ. Urinary eosinophil protein X in children with atopic asthma: a useful marker of antiinflammutory treatment. Allergy Clin Immunol 1996; 97:1179-87.
14. 14 Lugosi E, Halmerbauer G, Frischer T, Koller DY. Urinary eosinophil prolein X in relation to disease activity in childhood asthma. Allergy 1997; 52:584-8.
15. 15 National Asthma Education and Prevention Program. Expert panel report 2: Guidelines from the Diagnosis and Management of Asthma. US Dept 7, Health and Human Services, NIH Publication, 1997:97-4051A.
16. 16 Apple F, Brandt C, Prosch A et al. Creatinine clearance: enzymatic vs Jaffé determination of creatinine in plasma and urine. Clin Chem 1986; 32:388-90.
17. 17 Wempe JB, Tammeling EP, Koeter GH, Hakansson L, Venge P, Postma DS. Blood eosinophil numbers and activity during 24 hours: Effects of treatment with budesonide and bambuterol. J Allergy Clin Immunol 1992; 90:757-65.
18. 18 Martin RJ, Cicutto LC, Ballard RD. Factors related to the nocturnal worsening of asthma. Am Rev Respir Dis 1990; 141:33-8.
19. 19 Postma DS, Oosterhoff YA, Alderen WMC, Kauffmann HF, Wempe JB, Koeter CH. Inflammation in nocturnal asthma. Am J Respir Crit Care Med 1994; 150:83-6.
20. 20 Barnes PJ, Fitzgerald GA, Brown MJ, Dollery C. Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N Engl J Med 1980; 303:263-7.
21. 21 Stein RT, Holberg CJ, Morgan WJ et al. Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood. Thorax 1997; 52:946-52.
22. 22 Timonen KL, Nielsen J, Schwartz J et al. Chronic respiratory symptoms, skin test results, and lung function as predictors of peak flow variability. Am J Respir Crit Care Med 1997; 156:776-82.
23. 23 Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996; 154:21-7.
24. 24 Bousquet J, Chanez P, Lacoste JY et al. Indirect evidence of bronchial inflammation assessed by titration of inflammatory mediators in BAL fluid of patients with asthma. J Allergy Clin Immunol 1991; 88:649-60.